Abstract | BACKGROUND: METHODS: We analysed data from 13 Austrian health insurance funds for the years 2009 to 2014, on 72,676 patients with a hospital discharge diagnosis of ACS. The primary end point was recurrence of ACS or death >30days after the index event. RESULTS: 32,830 subjects received a prescription of a P2Y12 inhibitor within 30days after the index ACS. 18,640 (56.8%) subjects were discharged with clopidogrel, 6683 (20.4%) with prasugrel, and 7507 (22.9%) with ticagrelor, respectively. Data from 32,174 patients with 4975 events during a median follow-up period of 24.9months were available for survival analysis. The cumulative incidence for recurrence of ACS or death at two years was 18.7% in patients receiving clopidogrel, and 8.7% and 12.0% in those receiving prasugrel or ticagrelor, respectively. CONCLUSION: Utilization of P2Y12 inhibitors in patients with ACS was consistent with guideline recommendations. Prasugrel and ticagrelor are increasingly used in ACS patients and associated with a lower number of recurrence of ACS or death compared to clopidogrel. However, clopidogrel was predominantly used in older patients with more co-morbidities.
|
Authors | Safoura Sheikh Rezaei, Angelika Geroldinger, Georg Heinze, Berthold Reichardt, Michael Wolzt |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 235
Pg. 61-66
(May 15 2017)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 28262344
(Publication Type: Journal Article)
|
Copyright | Copyright © 2017. Published by Elsevier B.V. |
Chemical References |
- Platelet Aggregation Inhibitors
- Clopidogrel
- Prasugrel Hydrochloride
- Ticagrelor
- Adenosine
- Ticlopidine
- Aspirin
|
Topics |
- Acute Coronary Syndrome
(diagnosis, drug therapy, epidemiology)
- Adenosine
(analogs & derivatives, therapeutic use)
- Aged
- Aspirin
(therapeutic use)
- Austria
(epidemiology)
- Clopidogrel
- Drug Therapy, Combination
(methods, statistics & numerical data)
- Female
- Hospitalization
(statistics & numerical data)
- Humans
- Incidence
- Male
- Medication Therapy Management
(organization & administration, statistics & numerical data)
- Patient Discharge
(statistics & numerical data)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Prasugrel Hydrochloride
(therapeutic use)
- Recurrence
- Survival Analysis
- Ticagrelor
- Ticlopidine
(analogs & derivatives, therapeutic use)
|